Case Conversation: Perspectives on Early Thrombopoietin Receptor Agonist Use in Pediatric Immune Thrombocytopenic Purpura

This is a recorded version of the journal club, Case Conversation – Perspectives on Early Thrombopoietin Receptor Agonist Use in Pediatric ITP, that was presented live on Friday, January 30th, 2026. Please scroll all the way down this page to view the archived program.

Webinar Date: 1/30/2026
Estimated Time to complete: 1 hour
Format: Archived Webinar
Target Audience: 
This activity is designed for healthcare professionals, including hematologists, obstetricians, gynecologists, pediatricians, advanced practice providers, and nurses specializing in the care of women/girls are the primary target audience to ensure optimal comprehensive care.

Overview:
Immune thrombocytopenia (ITP) in children is commonly managed with observation or short-term first-line therapies; however, a substantial proportion of patients require pharmacologic intervention and experience treatment failure or relapse. While eltrombopag, a thrombopoietin receptor agonist, is FDA-approved for chronic pediatric ITP, its role in the newly diagnosed setting has remained uncertain.

Through a case-based discussion with our expert faculty, this program will explore the clinical implications of these findings, including patient selection, treatment goals, safety considerations, and the potential role of eltrombopag earlier in the disease course. The session will support clinicians in applying emerging evidence to optimize care for pediatric patients with newly diagnosed ITP and non-severe bleeding.

Learning Objectives
At the conclusion of this Program, participants may be able to:

1. Identify limitations of current first-line treatment approaches for pediatric patients with newly diagnosed immune thrombocytopenia who require pharmacologic intervention.
2. Evaluate patient selection criteria and clinical considerations for incorporating eltrombopag into the management of newly diagnosed pediatric immune thrombocytopenia with non-severe bleeding.
3. Integrate emerging evidence into clinical decision-making to optimize treatment strategies and improve outcomes for pediatric patients with immune thrombocytopenia.

Faculty:
Kristin A. Shimano, MD
Professor of Pediatrics
UCSF Benioff Children’s Hospitals

Amanda B. Grimes, MD
Director, Immune Hematology Program
Assistant Professor
Texas Children’s Hospital / Baylor College of Medicine

This activity is being supported by an educational grant from Sobi, Inc.

---